Research Article

Characterization of patients with primary biliary cholangitis and autoimmune hepatitis from a community hospital in East Harlem

Priyanka Yerragorla1#, Divya Nekkalapudi2#, Ahmed Shady3# and Nora V. Bergasa4*

Department of Medicine, New York City Health, Hospitals, Metropolitan, Pagny, New York Medical College, New York, USA

#Contributed equally to this work

Abstract

Background and objectives: Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) are uncommon autoimmune diseases in the United States. There is limited information in regards to those two conditions in Black Americans and subjects of Hispanic ethnicity; thus, we conducted a study to characterize patients with these diseases in a community hospital that serves this type of population

Methods: A retrospective review from 2001 to 2017 of all electronic medical records of patients with diagnoses of PBC or AIH according to the International Classification of Diseases (ICD 10) was conducted. This period was chosen because of feasibility.

Results: Fifteen patients with PBC were identified, one of whom was a man, all were of Hispanic ethnicity and all were in precirrhotic stages. The response to Ursodeoxycholic Acid (UDCA) was suboptimal, however, no complications from liver disease were identified during the study period.

Five women with AIH were identified, all were of Hispanic ethnicity, all were treated with prednisone and azathioprine with appropriate response.

Conclusions: Hispanic patients with AIH respond to treatment appropriately. However, patients with PBC exhibited a suboptimal response to UDCA.

Pharmacogenetic studies should be considered in Hispanic patients in regards to the use of UDCA.

Introduction

Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) are uncommon immune mediated chronic liver diseases [1–3]. Most of the literature on the epidemiology of these two conditions is derived from Caucasian populations; in the United States, there is limited information in regards to PBC and AIH in Black Americans and in subjects of Hispanic ethnicity [4–11].

New York City Health+Hospitals/Metropolitan serves the community of East Harlem, populated mostly by black Americans, black Africans and subjects of Hispanic ethnicity; accordingly, the aim of this study was to characterize the patients with AIH and PBC attended at this institution, and to explore communalities between them and patients from the country that gave the Hispanic community its language, Spain.

Methods

A retrospective review of medical records coded as PBC or AIH by the ICD 10 classification from 2001–2017 was conducted. This time period was chosen because of feasibility to access electronic medical records. The study was approved by the institutional review board.
Results

One patient was diagnosed with AIH at hospitalization for acute hepatitis; all other patients with AIH or PBC were referred to the hepatology clinic because of abnormal liver profile (Tables 1,2). None of the patients from either group had end stage liver disease or hepatocellular carcinoma over the period of the study.

Fifteen patients had a diagnosis of PBC, one of whom was a man; the mean age was 65 years, with a range of 38–91. All were of Hispanic ethnicity. The most common symptom was documented as pruritus in eight patients, all of whom were treated with cholestyramine, associated with relief, and fatigue in one. The coexistent autoimmune diseases were scleroderma in three patients and hypothyroidism also in three patients. No stigmata of chronic liver disease were documented from any of the patients.

Table 1: Selected laboratory data in patients with primary biliary cholangitis at diagnosis and at twelve months of treatment with ursodeoxycholic acid.

<table>
<thead>
<tr>
<th>Test</th>
<th>At the time of diagnosis</th>
<th>12 month post treatment initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST: mean ± SD (range) Normal: 35 - 75 U/L</td>
<td>50 ± 18.91 (18 - 87)</td>
<td>48.33 ± 22.86 (14 - 85)</td>
</tr>
<tr>
<td>ALT: mean ± SD (range) Normal: 30 - 65 U/L</td>
<td>53.71 ± 28.32 (25 - 104)</td>
<td>48.53 ± 27.67 (13 - 93)</td>
</tr>
<tr>
<td>ALP: mean ± SD (range) Normal: 50 - 136 U/L</td>
<td>250.42 ± 139 (93 - 517)</td>
<td>215.53 ± 124.19 (84 - 473)</td>
</tr>
<tr>
<td>Total Bilirubin: Mean ± SD (range) Normal: 0 - 1 mg/dl</td>
<td>0.64 ± 0.32 (0.25 - 1.1)</td>
<td>0.63 ± 0.28 (0.3 - 1.2)</td>
</tr>
<tr>
<td>Albumin: Mean ± SD (range) Normal: 3.4 - 5 g/dl</td>
<td>3.9 ± 0.58 (2.2 - 4.6)</td>
<td>3.9 ± 0.36 (3.4 - 4.6)</td>
</tr>
</tbody>
</table>

Abbreviations: AST: Aspartate Transaminase; ALT: Alanine Transaminase; ALP: Alkaline Phosphatase; SD: Standard Deviation.

Table 2: Selected laboratory data in patients with autoimmune hepatitis at diagnosis and at twelve months of treatment with immunossuppressants.

<table>
<thead>
<tr>
<th>Test</th>
<th>At the time of diagnosis</th>
<th>12 month post treatment initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST: mean ± SD (range) Normal: 15 - 37 U/L</td>
<td>103 ± 104.58 (27 - 287)</td>
<td>32.33 ± 6.3 (25 - 36)</td>
</tr>
<tr>
<td>ALT: mean ± SD (range) Normal: 30 - 65 U/L</td>
<td>136 ± 160.07 (19 - 417)</td>
<td>38.33 ± 20.7 (23 - 62)</td>
</tr>
<tr>
<td>ALP: mean ± SD (range) Normal: 50 - 136 U/L</td>
<td>131.8 ± 79.95 (72 - 251)</td>
<td>88 ± 29.4 (62 - 120)</td>
</tr>
<tr>
<td>Total Bilirubin: Mean ± SD (range) Normal: 0 - 1 mg/dl</td>
<td>1.88 ± 2.59 (0.3 - 6.5)</td>
<td>0.56 ± 0.23 (0.2 - 0.8)</td>
</tr>
<tr>
<td>Albumin: Mean ± SD (range) Normal: 3.4 - 5 g/dl</td>
<td>4.0 ± 0.3 (3.7 - 4.4)</td>
<td>3.76 ± 0.40 (3.76 - 4.2)</td>
</tr>
</tbody>
</table>

Abbreviations: AST: Aspartate Transaminase; ALT: Alanine Transaminase; ALP: Alkaline Phosphatase; SD: Standard Deviation.

In the group of patients with PBC, fourteen patients had positive Anti Mitochondrial Antibodies (AMA) in serum and eleven had Anti–Nuclear Antibodies (ANA). The mean serum IgG concentration was 1,592 mg/dL with a range of 1,130–3,280 (normal 690–1,140), and the mean IgM was 281 mg/dL with a range of 64–626 (normal 40–240). Five patients had probable PBC (i.e. chronic cholestatic liver profile and positive AMA) [12] and one was AMA negative but, liver histology was consistent with the disease. Of the patients in whom liver histology was available, five had stage I, four stage II and one stage IV [13]; four of the patients had steatosis. All had been treated with Ursodeoxycholic Acid (UDCA) from the time of diagnosis (Table 1) [14]. According to the Barcelona criteria [15] and based on the serum Alkaline Phosphatase (ALP) activity, three patients exhibited complete response, ten patients did not respond, and in the two patients with initially normal serum activity of ALP, it remained the same. The mean reduction in serum ALP activity was 14% (Figure 1). The globe score [16] in three of the fifteen patients (20%) at the end of one year of treatment predicted a low transplant free survival.

In the group of AIH there were five women of Hispanic ethnicity with a mean age of 51 years (range 41–66). One patient reported transient pruritus, which was treated with cholestyramine, associated with documented relief and one had icterus on exam, which resolved on treatment. Two patients had systemic lupus erythematosus and one had psoriasis. Of the five patients, three were positive for anti-smooth muscle antibody and four had ANA in their serum. The mean serum IgG was 1,164 mg/dl with a range of 940–2,040 (normal 690–1,140). Three patients had grade II and one had grade III inflammation on liver histology [17]; one patient had stage I fibrosis and three had stage II [17]. All were treated with prednisone and azathioprine or 6-mercaptopurine after diagnosis (Table 2).

Discussion

In this retrospective study of patients with PBC or AIH, the majority of patients was of Hispanic ethnicity and was precirrhotic, and the minority had other associated autoimmune diseases. Pruritus was the most common symptom in PBC. In association with treatment with UDCA at one year, only three patients (23%) exhibited complete response to the drug [15], with a small mean decrease in ALP activity. Liver profile normalized itself on immunosuppression in AIH.

The percentage of patients with PBC that reported pruritus was 53%, as compared to the 70% that has been consistently documented in the world literature [18]. In addition, only one patient (6%) reported fatigue, which is substantially lower than what has been reported in other studies, especially, in the recent literature [19]. This is an important observation because it has been proposed that most Hispanic patients with PBC report pruritus and fatigue in its majority [20]. We wonder if the absence of fatigue in our study group is a reflection of the need to survive in the challenging socio-economic situations that some of the patients from the community that the hospital serves may face, and that may not allow them to focus on lack of energy level.
In general, approximately 35% of patients do not experience a significant reduction in serum activity of ALP in association with UDCA [21,22]; these are patients who appear to have a decrease in survival free from liver transplantation [15,21-23]. In contrast to patients with AHI who responded well to the standard of care (i.e. immunosuppression), only three patients with PBC (23%) exhibited normalization in the serum ALP activity in association with UDCA. In fact, in our study the mean decrease in ALP activity at one year of treatment was only 14%; this finding may suggest that pharmacogenetics of patients of Hispanic ethnicity may play a role in their response to treatment with this medication [24].

The Globe score predicted a good transplant free survival in twelve of the fifteen patients (80%) at the end of one year of treatment. In this context, although the globe score predicted accurately in the majority of patients, it is worth noticing that this score was derived from data on the local population from eight European and North American countries, which are mostly comprised of non–Hispanic subjects, and, although some patients included in this derivation might have been of Hispanic ethnicity, the genesis of the score raises a question on the validity and applicability of the globe score on the Hispanic population in general.

Although the number of patients in this study is small, we would like to point out some similarities to those from the study from Spain. The prevalence of pruritus and fatigue from the study from Spain was 27 and 47 %, respectively [25], lower than what has been published by other groups [19], and also a finding in our study; this result may be the expression of the suggested genetic predisposition to be protected (or have susceptibility) from pruritus [26,27] (and fatigue). In addition, the combined percent of subjects that had incomplete or no response to UDCA was 77% in our study and 56% in the one from Spain [25], both higher than the 35% reported from other studies [21]. By definition, Hispanics are a heterogeneous population and as a group, they are underrepresented in research studies [24,28,29]. There is interethnic and intraethic variability in the genetics of metabolizing enzymes, which highlights the need to define the ancestries of the population studied in clinical trials, including patients of Hispanic ethnicity with PBC.

In contrast to the patients with PBC, those with AHI who were also of Hispanic ethnicity and who were treated with immunosuppression medications, showed biochemical remission with the treatment, suggesting that ethnicity may not have an impact on the response to this type of drug.

This study is limited by its retrospective nature; however, we can conclude that PBC and AHI are not common in the community of East Harlem, consistent with their definition as rare diseases [2,3]. Liver disease was promptly recognized at referral, as suggested by the pre-cirrhotic stages at diagnosis. Biochemical response to treatment was appropriate in AHI; however, in PBC, the response was lower than what has been considered optimal. Although lack of adherence to treatment cannot be unequivocally excluded, the effects of ethnicity on response to UDCA cannot be ignored; thus, pharmacogenetic studies in patients of Hispanic ethnicity with PBC merit consideration.

References


